Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open Access
- 1 September 2014
- journal article
- practice guideline
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_3) , iii83-iii92
Abstract
Mantle cell lymphoma (MCL) is a less frequent subtype of lymphoid malignancies and represents 6%–9% of malignant lymphoma in Western Europe. The annual incidence of this disease has increased during recent decades to 1–2/100 000 recently. MCL is more common in males than in women with a 3 : 1 ratio.Keywords
This publication has 62 references indexed in Scilit:
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 studyAnnals of Oncology, 2013
- A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphomaHaematologica, 2012
- Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersHaematologica, 2011
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphomaHaematologica, 2011
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyBlood, 2010
- Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphomaCancer, 2010
- Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909Journal of Clinical Oncology, 2009
- Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL NetworkJournal of Hematopathology, 2009
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008